BioSpace News Archive

Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “Company” or “Algernon”) a clinical stage pharmaceutical development company is pleased to provide a final summary of the common share purchase warrants of the Company (the “November Warrants”), that were issued on November 1, 2019.

Initial agreement provides up to 40 million doses to COVAX in 2021 First deliveries are expected to take place in Q1 2021 subject to the execution of supply agreements under the COVAX Facility structure

AIkido Pharma Inc. announced that on January 22, 2021, the Company received a letter from the Listing Qualifications Department of The NASDAQ Stock Market indicating that it has regained compliance with the $1.00 minimum bid price requirement for continued listing on The NASDAQ Capital Market under Listing Rule 5550.

UBC, a leading global late-stage and patient support services provider, has introduced UBC Pathways® Engage – a virtual patient engagement platform featuring a digital concierge named Linda, designed to create meaningful and long-lasting relationships.

Calcula Technologies, a company focused on improving kidney and ureteral stone treatment, announced the successful completion of their initial clinical cases following the recent FDA 510(k) clearance of the Peralta Stone Removal Catheter.

Nanoform Finland Plc, an innovative nanoparticle medicine enabling company, announced positive interim results from its clinical study.

Invitation to attend Vitrolife’s conference call regarding presentation of the Report on Operations 2020.

Boston Scientific Corporation (NYSE: BSX) has received U.S. Food and Drug Administration (FDA) approval of its fourth-generation Vercise Genus™ Deep Brain Stimulation (DBS) System.

Theralase Technologies Inc. ( TSXV:TLT )( OTCQB:TLTFF ), a clinical stage pharmaceutical company focused on the research and development of light activated Photo Dynamic Compounds and their associated drug formulations used to destroy various cancers, bacteria and viruses safely and effectively is pleased to announce that the Company has expanded its Intellectual property portfolio

Ten of the world’s leading biopharmaceutical companies today announced the formation of a new non-profit corporation, Accumulus Synergy, Inc., which is intended to support interactions between industry and health authorities worldwide to enable real-time collaboration and data exchange, as well as data submission.